Budesonide pharmacokinetics and systemic effects at steady state via HFA pMDI, CFC pMDI and Turbuhaler® in healthy volunteers

L. G. Carlsson, W. Kuhn, M. Carlholm, M. Gillen (Lund, Uppsala, Sweden; Wilmington, DE, United States Of America)

Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Session: Recent advances in the treatment and pathogenesis of asthma
Session type: Thematic Poster Session
Number: 3629
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
L. G. Carlsson, W. Kuhn, M. Carlholm, M. Gillen (Lund, Uppsala, Sweden; Wilmington, DE, United States Of America). Budesonide pharmacokinetics and systemic effects at steady state via HFA pMDI, CFC pMDI and Turbuhaler® in healthy volunteers. Eur Respir J 2008; 32: Suppl. 52, 3629

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Budesonide HFA pMDI is pharmacokinetically and clinically comparable with budesonide CFC pMDI in healthy volunteers, and in adults and children with asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 503s
Year: 2005

Comparison of systemic pharmacodynamic effects of two HFA formulations of formoterol fumarate delivered by pressurised metered dose inhaler in healthy subjects
Source: Annual Congress 2009 - New aspects of inhalation therapy
Year: 2009

Formoterol hydrofluoroalkane (HFA) pMDI has as rapid an onset of action as salbutamol HFA pMDI in asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 285s
Year: 2003

Same minimal effective dose of budesonide Turbuhaler® and fluticasone Diskus®/Accuhaler® in adult asthmatics
Source: Eur Respir J 2001; 18: Suppl. 33, 158s
Year: 2001

The novel budesonide HFA pMDI is clinically comparable to the conventional budesonide CFC pMDI in paediatric patients with asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 160s
Year: 2005

The anti-inflammatory effect of budesonide 800 μg/day via Easyhaler® compared with the same dose of budesonide via Turbuhaler® in adult asthmatics
Source: Eur Respir J 2001; 18: Suppl. 33, 337s
Year: 2001

Pharmacokinetic evaluation of two HFA pMDI formulations of salmeterol xinafoate administered through a spacer in healthy subjects
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011

Comparison of a new HFA 134a-formulated budesonide pMDI with a standard CFC-formulated budesonide pMDI in children with persistent asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 160s
Year: 2005

Efficacy and safety of new formulation of fluticasone propionate/salmeterol delivered via a HFA pMDI inhaler in patients with asthma
Source: Virtual Congress 2020 – Asthma inhalers: devices and adherence studies
Year: 2020


Comparison of the effects of beclomethasone HFA (BDP- HFA) pMDI with beclomethasone CFC (BDP-CFC) pMDI on 10-hour urinary cortisol in healthy subjects
Source: Annual Congress 2008 - Advances in the treatment and pathogenesis of pulmonary diseases
Year: 2008

Non-inferiority comparison of formoterol HFA (FM-HFA) pMDI with formoterol CFC (FM-CFC) pMDI in patients with symptomatic asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 358s
Year: 2007

Non-inferiority comparison of ipratropium-salbutamol HFA (IB/SAL-HFA) pMDI with ipratropium salbutamol CFC (IF/SAL-CFC) pMDI in patients with COPD
Source: Eur Respir J 2007; 30: Suppl. 51, 611s
Year: 2007

Non-inferiority comparison of budesonide HFA (BUD-HFA) pMDI with budesonide CFC (BUD-CFC) pMDI in patients with persistent moderate asthma
Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care
Year: 2008


Comparison of two budesonide powder inhalers, Giona Easyhaler® and Pulmicort Turbuhaler® in steroid-naive asthmatic patients
Source: Eur Respir J 2001; 18: Suppl. 33, 100s
Year: 2001

Systemic activity of beclometasone dipropionate HFA and CFC formulations in metered dose inhalers assessed by knemometry
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010

QVAR pMDI is more cost effective than CFC-beclometasone dipropionate (BDP) pMDI in a real-life asthmatic population initiating ICS
Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care
Year: 2009

Systemic effects and pharmacokinetics of a new CFC-free metered dose inhaler of beclomethasone dipropionate following multiple dosing in asthmatic patients
Source: Eur Respir J 2005; 26: Suppl. 49, 180s
Year: 2005

Evaluation of the systemic pharmacodynamic effects of two HFA formulations of Salmeterol xinafoate/Fluticasone propionate HFA pMDI 25/250 mcg
Source: International Congress 2017 – Inhalers and their use
Year: 2017

Does Clickhaler match the Turbuhaler for efficacy of inhaled budesonide?
Source: Eur Respir J 2005; 26: Suppl. 49, 339s
Year: 2005

Beclometasone/formoterol administered via extrafine dry powder inhaler in controlled asthmatic patients: Comparison with pMDI and beclometasone monotherapy
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012